Table 1.

Summary of published data on clinical impact of CTNNB1 mutations in EC.

Study	Setting	No. of cases	Outcome
Kurnit et al. 2017 [32]	Retrospective	342	Mutations of CTNNB1 were connected to worse recurrence free survival, tumours in younger patients, low-grade histology, and lower rates of LVI, PNI, and myometrial invasion.
Imboden et al. 2020 [4]	Retrospective	41	Mutations of CTNNB1 were most common type of mutations in primary tumours with low-grade histology.
Ruz-Caracuel et al. 2021 [52]	Retrospective	218	Mutations in exon 3 of CTNNB1 were significantly associated with decreased disease-free survival in patients with low-grade, early-stage EEC.
Stelloo et al. 2016 [55]	Retrospective	834	Mutations in exon 3 of CTNNB1 were prognostic for distant recurrence of the disease.
Costigan et al. 2021 [49]	Retrospective	79	Tumours with mutations of CTNNB1 had higher rate in patients with stage IA disease at diagnosis and included distant metastases.
Moroney et al. 2019 [56]	Case-control	15	Mutations of CTNNB1 are present at significantly higher rates in recurrent stage I, grade 1 endometrial cancers.
Liu et al. 2014 [18]	Retrospective	271	Mutations in exon 3 of CTNNB1 were statistically significantly correlated with younger patients in the TCGA cohort.